0000320017 2026-11-12 2026-11-12 0000320017 1 2026-11-12 2026-11-12 0000320017 2 2026-11-12 2026-11-12 shares iso4217:USD shares iso4217:USD pure S-8 S-8 Lisata Therapeutics, Inc. Equity false Common Stock, $0.0001 par value per share true 22378380 0.45 10070271 0.000087 876.12 Equity false Common Stock, $0.0001 par value per share true 423026 0.55 232664.3 0.000087 20.25 10302935.3 896.37 0 896.37 <table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"> <tr style="height: 0px; font-size: 0px;"><td style="width: 1%;"> </td><td style="width: 99%;"> </td></tr><tr style="vertical-align: top;"> <td style="padding: 0px 0pt;"> <div style="margin-bottom: 4pt;"> <span style="font-size: 10.0pt;">1</span> </div> </td> <td style="padding: 0px 5.4pt; text-align: left;"> <div style="margin-bottom: 4pt;"> <span style="font-size: 10.0pt;">Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of common stock of the Registrant that become issuable under the Marea Therapeutics, Inc. 2024 Stock Option and Grant Plan (the "2024 Plan") by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of the Registrant's common stock, as applicable. The amount registered represents shares of common stock reserved for issuance upon the exercise of outstanding stock options granted under the 2024 Plan. The proposed maximum aggregate offering price per unit and proposed maximum aggregate offering price for the 23,378,380 shares of common stock reserved for issuance upon the exercise of outstanding stock options granted under the 2024 Plan are made pursuant to Rule 457(h)(1) of the Securities Act solely for purposes of calculating the registration fee, and are calculated using the weighted-average exercise price of such stock options of $0.45 per share. </span> </div> </td> </tr> </table> <table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"> <tr style="height: 0px; font-size: 0px;"><td style="width: 1%;"> </td><td style="width: 99%;"> </td></tr><tr style="vertical-align: top;"> <td style="padding: 0px 0pt;"> <div style="margin-bottom: 4pt;"> <span style="font-size: 10.0pt;">2</span></div> </td> <td style="padding: 0px 5.4pt; text-align: left;"> <div style="margin-bottom: 4pt;"> <span style="font-size: 10.0pt;">Pursuant to Rule 416(a) promulgated under the Securities Act, this Registration Statement shall also cover any additional shares of common stock of the Registrant that become issuable under the M2 Therapeutics, Inc. 2025 Stock Option and Grant Plan (the "2025 Plan") by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of the Registrant's common stock, as applicable. The amount registered represents shares of common stock reserved for issuance upon the exercise of outstanding stock options granted under the 2025 Plan. The proposed maximum aggregate offering price per unit and proposed maximum aggregate offering price for the 423,026 shares of common stock reserved for issuance upon the exercise of outstanding stock options granted under the 2025 Plan are made pursuant to Rule 457(h)(1) of the Securities Act solely for purposes of calculating the registration fee, and are calculated using the weighted-average exercise price of such stock options of $0.55 per share.</span> </div> </td> </tr> </table> N/A 0000320017 EX-FILING FEES